Publications
Detailed Information
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Ham, Hye Seon | - |
dc.contributor.author | Kim, Min A. | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Kim, Woo Ho | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2009-05-22T05:13:07Z | - |
dc.date.available | 2009-05-22T05:13:07Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2008-05-27 | - |
dc.identifier.citation | BMC Cancer, Vol.8, p. 148 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.other | 91888 | - |
dc.identifier.uri | https://hdl.handle.net/10371/3699 | - |
dc.description.abstract | Background: The objective of this study was to evaluate the efficacy and toxicity of infusional 5-fluorouracil (5-FU), folinic acid and oxaliplatin (modified FOLFOX-6) in patients with advanced gastric cancer (AGC), as first-line palliative combination chemotherapy. We also analyzed the predictive or prognostic value of germline polymorphisms of candidate genes associated with 5-FU and oxaliplatin. Methods: Seventy-three patients were administered a 2 hour infusion of oxaliplatin (100 mg/m(2)) and folinic acid (100 mg/m(2)) followed by a 46 hour continuous infusion of 5-FU (2,400 mg/m(2)). Genomic DNA from the patients' peripheral blood mononuclear cells was extracted. Ten polymorphisms within five genes were investigated including TS, GSTP, ERCC, XPD and XRCC. Results: The overall response rate (RR) was 43.8%. Median time to progression (TTP) and overall survival (OS) were 6.0 months and 12.6 months, respectively. Toxicities were generally tolerable and manageable. The RR was significantly higher in patients with a 6-bp deletion homozygote (-6 bp/-6 bp) in TS-3'UTR (55.0% vs. 30.3% in +6 bp/+6 bp or +6 bp/-6 bp, p = 0.034), and C/A or A/ A in XPD156 (52.0% vs. 26.1% in C/C, p = 0.038). The-6 bp/-6 bp in TS-3'UTR was significantly associated with a prolonged TTP and OS. In a multivariate analysis, the 6-bp deletion in TS-3'UTR was identified as an independent prognostic marker of TTP (hazard ratio = 0.561, p = 0.032). Conclusion: Modified FOLFOX-6 chemotherapy appears to be active and well tolerated as first line chemotherapy in AGC patients. The 6-bp deletion in TS-3'UTR might be a candidate to select patients who are likely to benefit from 5-FU based modified FOLFOX-6 in future large scale trial. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | BioMed Central | - |
dc.title | Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1186/1471-2407-8-148 | - |
dc.citation.journaltitle | BMC Cancer | - |
dc.identifier.wosid | 000257250800001 | - |
dc.identifier.scopusid | 2-s2.0-47349119840 | - |
dc.citation.startpage | 148 | - |
dc.citation.volume | 8 | - |
dc.identifier.sci | 000257250800001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Kim, Woo Ho | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | THYMIDYLATE-SYNTHASE GENE | - |
dc.subject.keywordPlus | MESSENGER-RNA LEVELS | - |
dc.subject.keywordPlus | METASTATIC COLORECTAL-CANCER | - |
dc.subject.keywordPlus | PLATINUM-BASED CHEMOTHERAPY | - |
dc.subject.keywordPlus | PROMOTER ENHANCER REGION | - |
dc.subject.keywordPlus | HIGH-DOSE 5-FLUOROURACIL | - |
dc.subject.keywordPlus | FOLINIC ACID | - |
dc.subject.keywordPlus | FLUOROURACIL CHEMOTHERAPY | - |
dc.subject.keywordPlus | PALLIATIVE CHEMOTHERAPY | - |
dc.subject.keywordPlus | INFUSIONAL FLUOROURACIL | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.